Provention Bio

$16.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.63 (+3.94%) As of 5:43 PM UTC today

Why Robinhood?

You can buy or sell Provention Bio and other stocks, options, and ETFs commission-free!

About PRVB

Provention Bio, Inc. Common Stock, also called Provention Bio, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D); PRV-015 for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 for Crohn’s disease; PRV-3279 for the treatment of lupus; and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ. The listed name for PRVB is Provention Bio, Inc. Common Stock.

CEO

Ashleigh W. Palmer

Employees

Headquarters

Red Bank, New Jersey

Founded

2016

Market Cap

932.62M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

630.03K

High Today

$16.68

Low Today

$15.75

Open Price

$16.14

Volume

296.41K

52 Week High

$18.50

52 Week Low

$4.72

Collections

Analyst Ratings

100%

of 7 ratings

Buy

100%

Hold

Sell

PRVB Earnings

-$0.56

-$0.29

-$0.01

$0.26

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 11, Pre-Market